<DOC>
	<DOCNO>NCT00717951</DOCNO>
	<brief_summary>Docetaxol plus capecitabine regimen standard treatment anthracycline-pretreated patient advance breast cancer . Cisplatin important drug advance breast cancer potential effective drug triple negative breast cancer.The study primary objective : Assess ORR , TTP , TTF 2 year PFS rate docetaxol+capecitabine docetaxol+cisplatin . The second objective : Assess safety QOL .</brief_summary>
	<brief_title>A Randomised , Multi-Center Study Docetaxol Plus Capecitabine Cisplatin Anthracycline-Pretreated Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>The study main inclusion criterion are:1.age≥18 , KPS &gt; 70.2.anthracycline-pretreated patient advance breast cancer.3.at least 1 measurable lesion define modified RECIST criteria.4.screening laboratory value within follow parameter : ANC ≥1.5×109/L , Hemoglobin≥10.0 g/dl，Platelet≥100×109/L . 5. sign ICF The patient randomise two group : docetaxol+capecitabine docetaxol+cisplatin . According AE , dose adjust .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>age≥18y KPS≥ 70 pathologic diagnosis breast cancer least 1 measurable lesion define modified RECIST criterion screen laboratory value follow parameter : hemoglobin : ≥10.0 g/dl absolute neutrophils count : ≥1.5×109/L platelet : ≥100×109/L creatinine clearance rate : ≥60ml/min total bilirubin : ≤1.5 ×upper limit normal Alkaline phosphatase , Aspartate aminotransferase Alanine aminotransferase : ≤ 2.5×upper limit normal（≤5×upper limit normal liver metastasis present ) sign ICF woman child bear potential , negative serum urine pregnancy test result study entry . More 2 cytotoxic chemotherapy treatment regimens metastatic disease . prior exposure 5Fluorouracil continuous infusion . prior exposure docetaxol metastatic disease Any cancer within 5 year prior screen exception contralateral breast cancer , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>docetaxol</keyword>
	<keyword>capecitabine</keyword>
	<keyword>cisplatin</keyword>
</DOC>